Clinical trial · Observational
Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma
NCT02269995CI-TRIAL-00035625completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This surveillance's objectives are: 1. Unknown adverse reactions 2. Incidences of adverse drug reaction 3. Factors considered to have effect to safety and effectiveness
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| E7040 | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- E7040
- interventionNames
- Device: E7040
Primary outcomes (1)
- measure
- Safety and Tolerability as measured by Adverse Events
- timeFrame
- Up to 30 days
Secondary outcomes (1)
- measure
- Efficacy of DC bead as assessed by embolic performance
- timeFrame
- Up to 30 days
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion criteria: Patients with Hepatocellular carcinoma Exclusion criteria: None
References
Publications (1)
- BACKGROUNDJpn J Intervent Radiol. 2017;32:136-141.